Endoxifen is a small molecule commercialized by Atossa Therapeutics, with a leading Phase II program in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer). According to Globaldata, it is involved in 12 clinical trials, of which 5 were completed, 6 are ongoing, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Endoxifen’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The revenue for Endoxifen is expected to reach an annual total of $58 mn by 2035 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Endoxifen Overview

Endoxifen is under development for the treatment of HER2 negative breast cancer, mammographic breast density for women and breast cancer for men, recurrent ovarian cancer. It is administered through oral and topical route. The drug candidate is an active metabolite of tamoxifen. It acts by targeting estrogen receptor.

See Also:

It was also under development for gynecomastia.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Atossa Therapeutics Overview

Atossa Therapeutics (Atossa), formerly Atossa Genetics, is a clinical-stage biopharmaceutical company. It develops proprietary therapeutics and delivery methods for breast cancer and other breast conditions. The company’s pipeline pharmaceutical programs include endoxifen, an active metabolite of tamoxifen, used for the treatment of breast density and other breast health conditions. Atossa develops patented microcatheter technology to deliver fulvestrant as a potential treatment of ductal carcinoma through the nipple to site of early breast cancer. The company uses its proprietary intraductal microcatheter technology to deliver CAR-T cells into the ducts of the breast for the treatment of breast cancer. The company operates presence in Australia, the US and the UK. Atossa is headquartered in Seattle, Washington, the US.
The operating loss of the company was US$27.7 million in FY2022, compared to an operating loss of US$20.5 million in FY2021. The net loss of the company was US$27 million in FY2022, compared to a net loss of US$20.6 million in FY2021.

For a complete picture of Endoxifen’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.